PIONEERING THE NEXT GENERATION

OF TARGETED PSYCHOACTIVE MEDICATIONS

TSXV:  PSYB

Platform Technology Utilizing Metabolic Engineering and Optimization Techniques

Developing an efficient, patent-pending bacterial biosynthesis process for tryptamine production

Metabolic Engineering to Advance the Standard of Care

Targeted Treatment: Variation in hallucinogenic efficacy of Psilocybe mushrooms is likely due to variation in the relative concentration of these compounds

Industry Comparables

The antidepressant drug market was valued at USD 13.39 billion in 2018 and expected to reach USD 15.88 billion by 2025

Menu:

About Us:

PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues.

Investment Deck:

© 2020 by PSYBIO